Q3 EPS Forecast for Fate Therapeutics Increased by Analyst

Key Points

• Wedbush raised its Q3 2025 earnings estimate for Fate Therapeutics from ($0.38) to ($0.30) per share, reflecting a more optimistic outlook for the biopharmaceutical company.
• Fate Therapeutics' stock is currently rated as "Hold" by analysts, with an average price target of $3.58, while several firms have recently downgraded their price objectives significantly.
• The company reported a loss of ($0.29) EPS in its latest quarter, surpassing the consensus estimate of ($0.35) EPS, with revenues of $1.91 million compared to expectations of $1.16 million.

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Investment analysts at Wedbush increased their Q3 2025 earnings estimates for shares of Fate Therapeutics in a report released on Wednesday, August 13th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.30) per share for the quarter, up from their prior forecast of ($0.38). The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share. Wedbush also issued estimates for Fate Therapeutics' Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.40) EPS, FY2028 earnings at ($0.61) EPS and FY2029 earnings at ($0.59) EPS.

Several other research analysts have also commented on FATE. Barclays dropped their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Robert W. Baird dropped their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Needham & Company LLC restated a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, June 12th. Wells Fargo & Company lowered their target price on shares of Fate Therapeutics from $4.00 to $2.50 and set an "equal weight" rating on the stock in a research note on Wednesday, August 13th. Finally, Wall Street Zen upgraded shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday. One equities research analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Fate Therapeutics currently has an average rating of "Hold" and a consensus target price of $3.58.

Fate Therapeutics Trading Down 1.3%

FATE stock traded down $0.0150 during midday trading on Friday, reaching $1.1250. The company had a trading volume of 409,718 shares, compared to its average volume of 2,042,146. The company has a 50 day moving average of $1.15 and a two-hundred day moving average of $1.14. Fate Therapeutics has a 1 year low of $0.6611 and a 1 year high of $4.20. The company has a market capitalization of $129.75 million, a P/E ratio of -0.78 and a beta of 2.24.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%. The company had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.16 million.

Institutional Trading of Fate Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Headlands Technologies LLC bought a new stake in Fate Therapeutics in the 2nd quarter valued at $56,000. Bridgeway Capital Management LLC bought a new stake in Fate Therapeutics in the 2nd quarter valued at $28,000. Jane Street Group LLC boosted its holdings in Fate Therapeutics by 631.4% in the 2nd quarter. Jane Street Group LLC now owns 465,820 shares of the biopharmaceutical company's stock valued at $522,000 after purchasing an additional 402,129 shares during the period. Sei Investments Co. bought a new stake in Fate Therapeutics in the 2nd quarter valued at $76,000. Finally, Invesco Ltd. boosted its holdings in Fate Therapeutics by 19.6% in the 2nd quarter. Invesco Ltd. now owns 255,372 shares of the biopharmaceutical company's stock valued at $286,000 after purchasing an additional 41,869 shares during the period. 97.54% of the stock is owned by institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.